Home › Companies › Maze Therapeutics, Inc. › 2025-2026
At Maze Therapeutics, Inc.'s shareholder meeting held June 8, 2026, in the 2025-2026 proxy season, 51 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 456 separate fund positions. On the most widely held item on that ballot — Election of Class I Directors: Jason Coloma, Ph.D. — Maze Therapeutics, Inc.'s filing reports the nominee as elected, with 86% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Maze Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Maze Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 8, 2026: 3 items on Maze Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 2 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Maze Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Maze Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jason Coloma, Ph.D. | 35,792,536 | -- | -- | 5,926,467 | 2,941,026 | 86% | Elected | — |
| Elect Director: Neil Kumar, Ph.D. | 34,056,425 | -- | -- | 7,662,578 | 2,941,026 | 82% | Elected | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 44,557,778 | 728 | 101,523 | -- | 0 | 99.9% | Approved | — |
Source: Maze Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a Maze Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Jason Coloma, Ph.D.
Maze Therapeutics, Inc.’s own tally for this item (“Elect Director: Jason Coloma, Ph.D.”): 35,792,536 for, 5,926,467 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the two nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until such director's successor has been duly elected and qualified, or until such director's earlier death, resignation, disqualification, retirement, or removal.”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 4,163,041 for, 505,211 withheld, 55,560 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,611,710 | 0 | 4 | 779 | For |
| Fidelity | 1,111,825 | 0 | 0 | 0 | For |
| BlackRock | 1,053,133 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 186,654 | Withhold |
| State Street | 119,922 | 0 | 0 | 86 | For |
| First Trust | 0 | 0 | 0 | 66,169 | Withhold |
| TIAA | 57,692 | 0 | 0 | 0 | For |
| Equitable | 56,989 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 0 | 0 | 48,046 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 43,422 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 42,984 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 39,171 | Withhold |
| SEI | 0 | 0 | 0 | 30,690 | Withhold |
| JPMorgan | 29,889 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 29,479 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 20,923 | Withhold |
| Northern Trust | 18,434 | 0 | 0 | 0 | For |
| Lincoln Financial | 17,600 | 0 | 0 | 0 | For |
| Brighthouse | 6,002 | 0 | 0 | 9,223 | Mixed |
| Russell Investments | 0 | 0 | 0 | 13,203 | Withhold |
| Global X | 0 | 0 | 0 | 12,542 | Withhold |
| Bridge Builder Trust | 11,327 | 0 | 0 | 0 | For |
| Pacific Life | 10,230 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 8,875 | Withhold |
| Brinker Capital Destinations Trust | 627 | 0 | 0 | 7,247 | Mixed |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Neil Kumar, Ph.D.
Maze Therapeutics, Inc.’s own tally for this item (“Elect Director: Neil Kumar, Ph.D.”): 34,056,425 for, 7,662,578 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the two nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until such director's successor has been duly elected and qualified, or until such director's earlier death, resignation, disqualification, retirement, or removal.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 2,955,761 for, 1,712,490 withheld, 55,561 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,611,709 | 0 | 5 | 779 | For |
| Fidelity | 0 | 0 | 0 | 1,111,825 | Withhold |
| BlackRock | 1,053,133 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 186,654 | Withhold |
| State Street | 119,922 | 0 | 0 | 86 | For |
| First Trust | 0 | 0 | 0 | 66,169 | Withhold |
| TIAA | 0 | 0 | 0 | 57,692 | Withhold |
| Equitable | 42,489 | 0 | 0 | 14,500 | Mixed |
| CARILLON SERIES TRUST | 0 | 0 | 48,046 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 43,422 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 42,984 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 39,171 | Withhold |
| SEI | 0 | 0 | 0 | 30,690 | Withhold |
| JPMorgan | 29,889 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 29,479 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 20,923 | Withhold |
| Northern Trust | 0 | 0 | 0 | 18,434 | Withhold |
| Lincoln Financial | 17,600 | 0 | 0 | 0 | For |
| Brighthouse | 6,002 | 0 | 0 | 9,223 | Mixed |
| Russell Investments | 0 | 0 | 0 | 13,203 | Withhold |
| Global X | 0 | 0 | 0 | 12,542 | Withhold |
| Bridge Builder Trust | 11,327 | 0 | 0 | 0 | For |
| Pacific Life | 10,230 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 8,875 | Withhold |
| Brinker Capital Destinations Trust | 627 | 0 | 0 | 7,247 | Mixed |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Maze Therapeutics, Inc.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 44,557,778 for, 728 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 4,723,812 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,612,493 | 0 | 0 | 0 | For |
| Fidelity | 1,111,825 | 0 | 0 | 0 | For |
| BlackRock | 1,053,133 | 0 | 0 | 0 | For |
| Charles Schwab | 186,654 | 0 | 0 | 0 | For |
| State Street | 120,008 | 0 | 0 | 0 | For |
| First Trust | 66,169 | 0 | 0 | 0 | For |
| TIAA | 57,692 | 0 | 0 | 0 | For |
| Equitable | 56,989 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 48,046 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 43,422 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 42,984 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 39,171 | 0 | 0 | 0 | For |
| SEI | 30,690 | 0 | 0 | 0 | For |
| JPMorgan | 29,889 | 0 | 0 | 0 | For |
| Putnam | 29,479 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 20,923 | 0 | 0 | 0 | For |
| Northern Trust | 18,434 | 0 | 0 | 0 | For |
| Lincoln Financial | 17,600 | 0 | 0 | 0 | For |
| Brighthouse | 15,225 | 0 | 0 | 0 | For |
| Russell Investments | 13,203 | 0 | 0 | 0 | For |
| Global X | 12,542 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,327 | 0 | 0 | 0 | For |
| Pacific Life | 10,230 | 0 | 0 | 0 | For |
| American Century | 8,875 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 7,874 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 55,345,261 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.91% |
| 2 | Fidelity | 2.01% |
| 3 | BlackRock | 1.90% |
| 4 | Charles Schwab | 0.34% |
| 5 | State Street | 0.22% |
| 6 | First Trust | 0.12% |
| 7 | TIAA | 0.10% |
| 8 | Equitable | 0.10% |
| 9 | CARILLON SERIES TRUST | 0.09% |
| 10 | DRIEHAUS MUTUAL FUNDS | 0.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Third Rock Ventures | 9.80% | DEF14A |
| Entities affiliated with Frazier Life Sciences | 9.06% | DEF14A |
| Entities affiliated with Deep Track Capital, LP | 9.00% | DEF14A |
| Third Rock Ventures IV, L.P. | 8.08% | 13G |
| Frazier Life Sciences Public Fund, L.P. | 7.85% | 13G |
| Entities affiliated with ARCH Venture Partners and related entities | 7.44% | DEF14A |
| JANUS HENDERSON GROUP PLC | 5.17% | 13G |
| BlackRock | 4.64% | 13F |
| Vanguard Group | 3.07% | 13F |
| Jason Coloma, Ph.D. | 2.75% | DEF14A |
Percentages above are of 55,345,261 shares outstanding, as reported by Maze Therapeutics, Inc. on its Form 10-Q dated May 7, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Maze Therapeutics, Inc.’s 10-Q dated May 7, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Maze Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Maze Therapeutics (MAZE) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/maze-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.